Investor Presentaiton

TC TC BIOPHARM ACHIEVE1 (TCB008-001) Ph II UK Study Update BIOPHARM Safety Cohort (N=5) study completed as of July 2023 - - 7 patients screened, 1 screen failure, 1 patient discontinued prior to treatment with TCB0008, 4 patients dosed with one dose of TCB008 (7 X 107 cells administered IV), 1 patient dosed with two doses of TCB008 (7 x 107 cells administered IV) - None of the adverse events were considered related to TCB008 and no dose limiting toxicities were reported in these 5 patients • All 5 patients reported treatment emergent serious adverse events (TESAEs) and all experienced at least one TESAES, however none were considered related to TCB008. 2 patients died during the study (post transplant lymphoproliferative disorder and disease progression), 2 patients withdrew consent, and 1 subject was withdrawn due to disease progression. ■ The best overall response per ELN 2020 Criteria was stable disease (2 patients, 40%) ■ DSMB review meeting occurring end of September 2023 11

View entire presentation